Celgene


Celgene

Infobox Company
company_name = Celgene
company_
company_type = Public nasdaq|CELG
foundation = 1986
location = Summit, New Jersey
industry = Healthcare, Biotechnology, Pharmaceutical company
products = THALOMID, REVLIMID
num_employees = 1,287 (2007)
homepage = [http://www.celgene.com/ www.celgene.com]

Celgene Corporation nasdaq|CELG is a manufacturer of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. As of January 1, 2007, the company had 1,287 full-time employees, 725 of whom were engaged primarily in research and development activities.cite web | url = http://www.sec.gov/Archives/edgar/data/816284/000093041307001678/c45786_10k.txt | title = Celgene's 2006 10-K| accessdate = 2007-09-03 | publisher = SEC] The company's major products are THALOMID (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and REVLIMID (lenalidomide), for which the company has received FDA and EMEA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. REVLIMID is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both THALOMID and REVLIMID are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Celgene also receives royalties from Novartis Pharma AG on sales of the entire RITALIN family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD).

Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.

History

In 1986, Celgene, originally a unit of the Celanese Corporation, was spun off as an independent company following the merger of Celanese Corporation with American Hoechst Corporation.

In July 1998, Celgene received approval from the FDA to market THALOMID for the acute treatment of the cutaneous manifestations of moderate to severe ENL.

In April 2000, Celgene reached an agreement with Novartis Pharma AG to license d-MPH, Celgene's chirally pure version of RITALIN. The FDA subsequently granted approval to market d-MPH, or FOCALIN, in November 2001.

In August 2000, Celgene acquired Signal Pharmaceuticals, Inc., a privately held company that searches for and develops pharmaceuticals that regulate disease-related genes. Signal Pharmaceuticals, Inc. now operates as Celgene Research San Diego, a wholly owned subsidiary of Celgene Corporation.

In December 2002, Celgene acquired Anthrogenesis, a privately held New Jersey-based biotherapeutics company and cord blood banking business, which is developing technology for the recovery of stem cells from placental tissues following the completion of full-term successful pregnancies. Anthrogenesis now operates as Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene. In December 2005, Celgene received approval from the FDA to market REVLIMID for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

In May 2006, Celgene received approval for THALOMID in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.

In June 2007, Celgene received full marketing authorization for REVLIMID in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy by the European Commission.

In March 2008, Celgene closed its $2.9 billion acquisition of Pharmion Corporation.

Products

References

External links

* [http://www.celgene.com Official website]


Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Celgene — Corporation Rechtsform Corporation ISIN US1510201049 Gründung …   Deutsch Wikipedia

  • Celgene Corporation — Logo de Celgene Corporation Création 1986 …   Wikipédia en Français

  • CELG — Celgene Corporation (Business » NASDAQ Symbols) …   Abbreviations dictionary

  • Thalidomide — This article is about the drug. For the musical about a person with thalidomide disability, see Thalidomide!! A Musical. Thalidomide Systematic (IUPAC) name (RS) 2 (2,6 dioxopiperidin 3 yl) 1H isoind …   Wikipedia

  • Softenon — Strukturformel Allgemeines Freiname Thalidomid …   Deutsch Wikipedia

  • Thalidomid — Strukturformel Allgemeines Freiname Thalidomid …   Deutsch Wikipedia

  • Lenalidomid — Strukturformel (R) Form (links) und (S) Form (rechts) …   Deutsch Wikipedia

  • Orphan-Arzneimittel — Der Begriff Orphan Arzneimittel oder Orphan Drug (von englisch orphan, „die Waise“, aus griechisch ορφανός) wurde 1983 erstmals für Arzneimittel verwendet, die für die Behandlung seltener Krankheiten eingesetzt werden. Eine genauere… …   Deutsch Wikipedia

  • Revlimid — Strukturformel (R) Form (links) und (S) Form (rechts) Allgemeines Freiname …   Deutsch Wikipedia

  • 5q-minus-Syndrom — Klassifikation nach ICD 10 D46 5q minus Syndrom (Myelodysplastisches Syndrom) ICD O 9986/3 Q93.5 Sonstige Deletionen eines Chromosomenteils …   Deutsch Wikipedia


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.